T
Thomas Soliman
Researcher at Medical University of Vienna
Publications - 54
Citations - 1400
Thomas Soliman is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 18, co-authored 45 publications receiving 1152 citations. Previous affiliations of Thomas Soliman include Vienna General Hospital & University of Vienna.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation
Thomas Soliman,Hubert Hetz,Christoph Burghuber,Georg Györi,Gerd R. Silberhumer,Rudolf Steininger,Ferdinand Mühlbacher,Gabriela A. Berlakovich +7 more
TL;DR: Short‐term ATG induction therapy with delayed administration of calcineurin inhibitors led to a more favorable rejection rate and an improved clinical course in case of a rejection episode.
Journal ArticleDOI
Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation.
Herwig Pokorny,T. Gruenberger,Thomas Soliman,Susanne Rockenschaub,Friedrich Längle,Rudolf Steininger +5 more
TL;DR: The hypothesis that primary graft function is of major importance for the long-term survival of liver transplants is confirmed, which leads to the interpretation that patients with a poor primary function have the worst survival prognosis and may be candidates for early retransplantation.
Journal ArticleDOI
Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis.
Gerd R. Silberhumer,Herwig Pokorny,Hubert Hetz,Harald Herkner,Susanne Rasoul-Rockenschaub,Thomas Soliman,Thomas Wekerle,Gabriela A. Berlakovich,Rudolf Steininger,Ferdinand Muehlbacher +9 more
TL;DR: The combination of a liver recipient with worsening &Dgr;-MELD and a potential donor with at least two EDC should be avoided.
Journal ArticleDOI
Influence of cumulative number of marginal donor criteria on primary organ dysfunction in liver recipients.
Herwig Pokorny,Felix B. Langer,H Herkner,R Schernberger,Walter Plöchl,Thomas Soliman,Rudolf Steininger,Ferdinand Muehlbacher +7 more
TL;DR: The aim of this cohort study was to assess the cumulative effect of marginal donor criteria on initial graft function and patient survival after liver transplantation.